VOYA Investment Management
GYRE icon

VOYA Investment Management’s Gyre Therapeutics GYRE Stock Holding History

VOYA Investment Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,442
Closed -$55K – 2849
2021
Q1 		$55K Hold
1,442
– – ﹤0.01% 2738
2020
Q4 		$68K Buy
+1,442
New +$62.4K ﹤0.01% 2626

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

VOYA Investment Management's GYRE Position: Q2 2021 in Review

VOYA Investment Management sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 1,442 shares — an estimated $55K sold.

VOYA Investment Management first reported a position in GYRE in Q4 2020 and held it in 2 quarters. The position peaked at $68K in Q4 2020. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • VOYA Investment Management reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • VOYA Investment Management sold 1,442 Gyre Therapeutics shares in Q2 2021, an estimated $55K.
  • VOYA Investment Management first reported a position in Gyre Therapeutics in Q4 2020 and held it in 2 quarters.
  • VOYA Investment Management's Gyre Therapeutics position peaked at $68K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on VOYA Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.